Scientific Publication

Popular weight-loss drugs are linked to fewer ER visits for chronic migraine, a new study finds, sparking hope and questions about a new treatment frontier.

A pivotal trial for a rare muscle disease failed its main goal, but promising data in a specific patient group offers a new, complex path forward.

A new drug, JIN-A02, shows early promise in overcoming resistance to common lung cancer therapies, even shrinking hard-to-treat brain metastases.

At a key summit, Candel Therapeutics will showcase how its oncolytic virus, CAN-3110, uses biomarkers to fight one of the deadliest brain cancers.

A new FDA-approved device offers a drug-free alternative for severe rheumatoid arthritis. Rush University is the first in Chicago to implant the system.

Relay Therapeutics' experimental drug, zovegalisib, offers new hope for a common and hard-to-treat form of advanced breast cancer with a promising safety profile.

A new liquid biopsy more accurately predicts cancer recurrence than standard methods, offering new hope and clarity for patients after surgery.

Myriad Genetics is launching a new cancer test that promises to detect recurrence earlier than ever. But can it win in a competitive market?

Propanc Biopharma is taking a 100-year-old cancer treatment concept into modern human trials, targeting advanced tumors and expanding into fibrosis.

Early data shows QurAlis' QRL-101 successfully engaged its intended target in ALS patients, a key step for a novel drug aimed at quelling neuronal storm.

Natera's Signatera test salvaged key insights from a failed clinical trial, creating a new roadmap for personalized breast cancer treatment and logistics.